Nicergoline in the treatment of neuropathic bladder dysfunction: a preliminary report.
We have employed the alpha blocking drug Nicergoline in 14 patients with neuropathic bladder dysfunction of the upper motor neurone type. The oral administration of 15-30 mgrs/day of this drug over a period of 9.5 months significantly improved the urodynamic parameters, with an increase of bladder capacity, a disappearance or amelioration of uninhibited bladder contractions and a decrease in urethral pressure, profile urethral length and residual urine. Two patients with vesico-ureteral reflux present before treatment showed radiological improvement after Nicergoline administration. Tolerance of Nicergoline had been excellent without appreciable side effects. In conclusion, Nicergoline seems to be active and well tolerated in the pharmacological treatment of neuropathic bladder dysfunction.
D000293:Adolescent; D000328:Adult; D002648:Child; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009530:Nicergoline / Q000627:therapeutic use*; D011859:Radiography; D013997:Time Factors; D001743:Urinary Bladder / Q000187:drug effects / Q000503:physiopathology; D001750:Urinary Bladder, Neurogenic / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects; D014718:Vesico-Ureteral Reflux / Q000188:drug therapy
D004873:Ergolines; D009530:Nicergoline